Engrail Therapeutics, a San Diego-based biotechnology company, has raised another $157 million to support its work developing precision medicines for psychiatric conditions and rare disorders. The ...
SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today ...
SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company) today announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment ...
San Diego-based biotech Engrail Therapeutics has raised $32 million as it looks to kick-start its first clinical work for its central nervous system med. Nan Fung Life Sciences (NFLS), the global ...
SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The ...
SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives ...
ENX-102 is an investigational GABA-A α2,3,5 positive allosteric modulator that blocks α1 The ENCALM Trial is a multi-center phase 2 trial to evaluate the efficacy and safety of ENX-102 as a ...
Mumbai: Medicine for anxiety and depression without any of the known side effects of the currently available therapies—that's the promise upon which Engrail Therapeutics has raised $157 million of ...
Engrail Therapeutics, a biotech startup led by Vikram Sudarsan, former executive of Indian pharmaceutical major Cipla, has secured $157 million (Rs 1300 crore) in its Series B round of funding, co-led ...
San Diego-based pharmaceuticals startup Engrail Therapeutics, which is focused on neuroscience pharmaceuticals, said today that it has raised an additional $32M in its Series A funding round, bringing ...
Post-traumatic stress disorder (PTSD) is a condition with limited effective therapeutic options to date, where 5-HT2A receptor agonists show promise for enhancing cortical plasticity in the brain and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results